Dec 2025 (Q3 FY26) — Jan 29, 2026
Takeda Q3 FY26 — Strong Pipeline Progress Offsets VYVANSE LOE and Market Headwinds
Read the full callTakeda (TAK) earnings
- Dec 2025 (Q3 FY26)
- Mar 2025
Takeda earnings: last reported Thu, 29 Jan 2026, for the quarter ended Dec 2025.
Price
$19.61 −0.31% · −$0.06
Performance +39.7% 1Y
1Y: $14.04 on 17 Oct 2025 → $19.61. High $19.67 (16 Oct 2026), low $13.23 (30 Oct 2025).
- Previous close
- $19.67
- 52-week range
- $13.23 – $19.67
- One year
- +39.28%
Overview
- Symbol
- TAK
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- US
- Currency
- USD
Call summaries
Sep 2025 (Q2 FY25) — Oct 30, 2025
Takeda Q2 FY25 — VYVANSE LOE Peaks, Pipeline Advances, and Innovent Partnership Bolsters Oncology
Read the full callEvery analysed call
Takeda earnings calls (TAK)
Financials
What the filings say
| Line item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Total liabilities | 19,616 | 77,719 | 74,542 | 69,848 | 61,530 | 57,099 | 51,788 | 48,920 |
| Fixed assets | 5,041 | 12,027 | 12,768 | 13,129 | 12,995 | 12,701 | — | — |
| Total assets | 38,560 | 124,549 | 118,082 | 116,598 | 108,192 | 104,823 | 99,869 | 95,321 |
| Line item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 3,548 | 2,966 | 6,168 | 9,129 | 9,221 | 7,338 | 4,735 | 7,073 |
| Cash from investing | -876 | -25,606 | 2,690 | 3,554 | -1,627 | -4,559 | -3,066 | -2,456 |
| Cash from financing | -3,063 | 26,605 | -9,258 | -9,828 | -8,787 | -5,326 | -2,343 | -5,027 |
| Capital expenditure | -629 | -701 | -1,170 | -1,004 | -1,012 | -1,056 | -1,160 | -1,343 |
| Free cash flow | 2,919 | 2,265 | 4,998 | 8,125 | 8,209 | 6,282 | 3,576 | 5,729 |
Insider filings
55 filings between Apr 27, 2026 and Sep 14, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$13.09M
20 sales by 13 insiders
10% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 35
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Plump Andrew Stewart | — | $5.34M | Sep 2, 2026 |
| Kim Julie So-Young | — | $1.52M | Aug 10, 2026 |
| Duprey Lauren Rusckowski | — | $1.45M | Sep 14, 2026 |
| Greenway Nicola Deidre Petal | — | $956.7K | Aug 18, 2026 |
| Bitetti Teresa Marie | — | $855.2K | Aug 10, 2026 |
| Platford Giles Richard | — | $531.5K | Aug 10, 2026 |
| Furney Natalie Anne Marie | — | $527.8K | Aug 10, 2026 |
| Ricci Gabriele | — | $429.0K | Aug 10, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 14, 2026 | Duprey Lauren Rusckowski Chief Transformation Officer | Sale | 34,535 | $640.3K |
| Sep 2, 2026 | Plump Andrew Stewart President, R&D | Sale 10b5-1 plan | 116,191 | $2.15M |
| Aug 19, 2026 | Plump Andrew Stewart President, R&D | Sale 10b5-1 plan | 19,651 | $363.3K |
| Aug 18, 2026 | Greenway Nicola Deidre Petal Chief Human Resources Officer | Sale | 12,980 | $235.1K |
| Aug 11, 2026 | Shannon Elaine Mary Pres., Global Supply & Quality | Sale | 20,363 | $357.4K |
| Aug 10, 2026 | Plump Andrew Stewart President, R&D | Sale | 165,393 | $2.83M |
| Aug 10, 2026 | Duprey Lauren Rusckowski Chief Transformation Officer | Sale | 47,586 | $813.7K |
| Aug 10, 2026 | Pacheco Rhonda Janice President, U.S. Business Unit | Sale | 16,901 | $289.0K |
| Aug 10, 2026 | Ibrahim Ramy Riad Ahmed President, PDT BU | Sale | 7,277 | $124.4K |
| Aug 10, 2026 | Farajallah Awny Samaan Botros Chief Medical Officer | Sale | 14,006 | $239.5K |
| Aug 10, 2026 | Greenway Nicola Deidre Petal Chief Human Resources Officer | Sale | 6,774 | $115.8K |
| Aug 10, 2026 | Greenway Nicola Deidre Petal Chief Human Resources Officer | Sale | 975 | $17.1K |
| Aug 10, 2026 | Greenway Nicola Deidre Petal Chief Human Resources Officer | Sale | 33,628 | $588.7K |
| Aug 10, 2026 | Furney Natalie Anne Marie Global General Counsel | Sale | 30,868 | $527.8K |
| Aug 10, 2026 | Platford Giles Richard President, IBU | Sale | 31,083 | $531.5K |
| Aug 10, 2026 | Kim Julie So-Young President and CEO | Sale | 89,090 | $1.52M |
| Aug 10, 2026 | Bitetti Teresa Marie President, OBU | Sale | 50,012 | $855.2K |
| Aug 10, 2026 | Shannon Elaine Mary Pres., Global Supply & Quality | Sale | 3,978 | $68.0K |
| Aug 10, 2026 | Pignagnoli Agosti Marcello Head, Strat. & Port. Dev | Sale | 22,957 | $392.6K |
| Aug 10, 2026 | Ricci Gabriele Chief Data & Tech. Officer | Sale | 25,088 | $429.0K |
| Jul 1, 2026 | Stoffels Paulus Director | Award | 3,800 | $0 |
| Jul 1, 2026 | BROUSSARD BRUCE D Director | Award | 3,800 | $0 |
| Jul 1, 2026 | Iijima Masami Director | Award | 1,800 | $0 |
| Jul 1, 2026 | Reed Kimberly A. Director | Award | 3,800 | $0 |
| Jul 1, 2026 | MARAGANORE JOHN Director | Award | 3,800 | $0 |
| Jul 1, 2026 | GILLIS STEVEN Director | Award | 3,800 | $0 |
| Jul 1, 2026 | Plump Andrew Stewart President, R&D | Award | 125,390 | $0 |
| Jul 1, 2026 | Kim Julie So-Young President and CEO | Award | 50,434 | $0 |
| Jul 1, 2026 | Kim Julie So-Young President and CEO | Award | 22,800 | $0 |
| Jul 1, 2026 | Bitetti Teresa Marie President, OBU | Award | 43,886 | $0 |
| Jul 1, 2026 | Duprey Lauren Rusckowski Chief Transformation Officer | Award | 45,140 | $0 |
| Jul 1, 2026 | Shannon Elaine Mary Pres., Global Supply & Quality | Award | 30,094 | $0 |
| Jul 1, 2026 | Ricci Gabriele Chief Data & Tech. Officer | Award | 37,616 | $0 |
| Jul 1, 2026 | Pignagnoli Agosti Marcello Head, Strat. & Port. Dev. | Award | 27,586 | $0 |
| Jul 1, 2026 | Pacheco Rhonda Janice President, U.S. Business Unit | Award | 50,156 | $0 |
| Jul 1, 2026 | Furney Natalie Anne Marie Global General Counsel | Award | 43,886 | $0 |
| Jul 1, 2026 | Farajallah Awny Samaan Botros Chief Medical Officer | Award | 17,554 | $0 |
| Jul 1, 2026 | Greenway Nicola Deidre Petal Chief Human Resources Officer | Award | 22,570 | $0 |
| Jul 1, 2026 | Ibrahim Ramy Riad Ahmed President, PDT BU | Award | 25,078 | $0 |
| Jul 1, 2026 | Smoter Jennifer Marie Chief Comm. & Gov. Officer | Award | 18,808 | $0 |
| Jul 1, 2026 | Platford Giles Richard President, IBU | Award | 49,558 | $0 |
| Jul 1, 2026 | Furuta Milano Chief Financial Officer | Award | 12,300 | $0 |
| Jul 1, 2026 | Miyabashira Asuka President, Japan Pharma B.U. | Award | 1,500 | $0 |
| Jul 1, 2026 | Tsusaka Miki Director | Award | 1,800 | $0 |
| Jul 1, 2026 | Kimura Koichiro Director | Award | 1,800 | $0 |
| Apr 27, 2026 | Kim Julie So-Young CEO - Elect | Award | 105,416 | $0 |
| Apr 27, 2026 | Duprey Lauren Rusckowski Chief Transformation Officer | Award | 59,990 | $0 |
| Apr 27, 2026 | Bitetti Teresa Marie President, OBU | Award | 64,988 | $0 |
| Apr 27, 2026 | Ricci Gabriele Chief Data & Tech. Officer | Award | 34,994 | $0 |
| Apr 27, 2026 | Plump Andrew Stewart President, R&D | Award | 212,470 | $0 |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for TAKEDA PHARMACEUTICAL CO LTD
Free account. Everything above stays public.
Write why you follow TAKEDA PHARMACEUTICAL CO LTD and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading